| Drug Name |
Cabozantinib s-malate |
| Drug ID |
BADD_D00331 |
| Description |
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.[L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] |
| Indications and Usage |
Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer.[L15123] It is also indicated for the treatment of advanced renal cell carcinoma and for hepatocellular carcinoma in patients previously treated with sorafenib.[L15128,L15133] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EX07 |
| DrugBank ID |
DB08875
|
| KEGG ID |
D10095
|
| MeSH ID |
C558660
|
| PubChem ID |
25102846
|
| TTD Drug ID |
D0IQ6P
|
| NDC Product Code |
55679-116; 59057-013; 83137-0002 |
| UNII |
DR7ST46X58
|
| Synonyms |
cabozantinib | Cometriq | XL 184 | XL184 cpd | XL-184 | BMS 907351 | BMS907351 | BMS-907351 |
